Latest Market Expectations News

Renergen Limited forecasts a significant increase in its loss per share for the six months ending August 2025, driven by one-off transaction expenses and full commissioning costs of its Phase 1 plant.

Bank of Queensland Limited announces a fully franked quarterly distribution of AUD 1.2182 per Capital Note 3 security, reflecting a 4.89% annualised yield tied to the 3-month BBSW plus margin.

EVE Health Group has begun distributing Dyspro™, a novel cannabinoid-based treatment for dysmenorrhoea and endometriosis, through a national telehealth partnership. This launch targets a significant unmet need in women’s health with a growing global market.

CloudHolter Pty Ltd reported a substantial $39.7 million net loss for FY2025 amid ongoing cash outflows but continues to raise capital through convertible notes as it targets an IPO by year-end.

Whitebark Energy has finalized the sale of its remaining 10% interest in the Wizard Lake assets to Conflux Energy, marking a strategic shift to focus on Australian projects.

Worley Limited has affirmed its FY25 earnings were consistent with prior guidance and analyst expectations, with only a minor margin outperformance deemed immaterial. The company confirms compliance with ASX continuous disclosure rules following an ASX inquiry.

Ramsay Health Care has clarified that its underlying earnings for FY25 aligned closely with market consensus, despite a significant non-cash impairment impacting statutory profits. The company confirms compliance with ASX disclosure rules amid share price volatility.

RPMGlobal Holdings clarifies the reasons behind withdrawing its FY2025 earnings guidance following the divestment of its Advisory business, providing detailed updates on software segment performance and compliance with ASX disclosure rules.

Woolworths Group has confirmed its full-year earnings for 2025 met market expectations, responding comprehensively to ASX inquiries about potential material variances. The retailer’s underlying results closely matched analyst consensus, despite statutory impairments and restructuring costs.

Telix Pharmaceuticals has secured FDA agreement on a resubmission plan for its glioma imaging agent TLX101-CDx, aiming for a Q4 2025 filing that includes additional efficacy data. The FDA signals likely expedited review, underscoring the unmet medical need.

Livium Ltd has inked a term sheet with the University of Melbourne to exclusively commercialise innovative microwave technology for rare earth elements extraction, promising high recovery rates and major energy savings.

Latitude 66 Limited has responded to an ASX price query concerning unusual trading activity, confirming no undisclosed material information exists and referencing prior announcements about a joint venture sale and recent assay results.